Connect
MJA
MJA

Potential impact of AUSFTA on Australia's blood supply

Wolfgang Frenzel
Med J Aust 2007; 186 (8): 427-430.
Published online: 16 April 2007

In reply: I would like to respond to the letter by Kennedy et al regarding the passive transfer of human T-lymphotropic virus (HTLV) antibodies following Octagam (intravenous immunoglobulin [IVIg]) administration.

  • Wolfgang Frenzel

  • Octapharma, Vienna, Austria


Competing interests:

Octapharma is the manufacturer of Octagam. I am employed by Octapharma in the role of International Medical Director.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.